Cardio-oncology & otherMeta-analysis
SGLT2 Inhibitors in Cardio-Oncology
- meta-analysis
- random-effects models
- meta-regression
- observational studies
Authors' conclusion
In patients with cancer, SGLT2i appear safe and are associated with fewer deaths and HF events, although substantial heterogeneity was observed across studies. Randomized controlled trials are warranted to confirm these hypothesis-generating findings.
Study context
- Population
- Adult patients with cancer (>18 years); nearly all had diabetes mellituspatients in thirteen observational studies
- Participants
- 107,126 patients
- Comparison
- SGLT2i in adult patients with cancer
Pooled result
As reported in the abstract
All-cause mortality
RR with SGLT2i (lower all-cause mortality)
0.47; 95% CI: 0.38-0.58
I2
96.30%
P
P < 0.001
Further pooled results
Heart failure (HF) composite (new-onset HF and/or HF hospitalization)
- RR with SGLT2i (significantly reduced)
- 0.48; 95% CI: 0.29-0.78
- I2
- 87.01%
- no evidence that background therapies modified the effect (all P > 0.05)
Atrial fibrillation/atrial flutter
- RR with SGLT2i (lower risk)
- 0.57; 95% CI: 0.42-0.76
- I2
- 66.4%
- P
- P < 0.001
Study characteristics
- Median age (years)
- 67.6 (IQR: 62.5-71.0)
- Median follow-up (months)
- 24 (IQR: 19.2-29.0)
Original publication
SGLT2 Inhibitors in Cardio-Oncology. JACC Adv. Published 14 May 2026. doi:10.1016/j.jacadv.2026.102790
Summarised from the published abstract; every number is checked against it